SEC Comment Letter 0000000000-24-002244 to ELITE PHARMACEUTICALS INC /NV/ (ELTP)

ELITE PHARMACEUTICALS INC /NV/
Date: Feb. 28, 2024 · CIK: 0001053369 · Accession: 0000000000-24-002244

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-15697

Date

February 28, 2024

Author

Carter Ward

Form

UPLOAD

Company

ELITE PHARMACEUTICALS INC /NV/

Letter

United States securities and exchange commission logo February 28, 2024 Carter Ward Chief Financial Officer ELITE PHARMACEUTICALS INC /NV/ 165 Ludlow Avenue Northvale, NJ 07647 Re:ELITE PHARMACEUTICALS INC /NV/ Form 10-K for the Fiscal Year Ended March 31, 2023 Filed June 29, 2023 File No. 001-15697 Dear Carter Ward: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
February 28, 2024
Carter Ward
Chief Financial Officer
ELITE PHARMACEUTICALS INC /NV/
165 Ludlow Avenue
Northvale, NJ 07647
Re:ELITE PHARMACEUTICALS INC /NV/
Form 10-K for the Fiscal Year Ended March 31, 2023
Filed June 29, 2023
File No. 001-15697
Dear Carter Ward:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io